01—Abstract
Summary
Summary of the 8-K filed March 6, 2026. Cited figures are marked; the original filing is the authoritative source.
Incyte Corporation disclosed in this Form 8-K, filed March 6, 2026, that the U.S. Food and Drug Administration issued a Complete Response Letter on February 27, 2026 for the supplemental Biologics License Application for Zynyz (retifanlimab-dlwr) 375mg.
The sBLA sought an additional indication for adult patients with metastatic non-small cell lung cancer in combination with platinum-based chemotherapy, and was supported by positive efficacy and safety data from the Phase 3 POD1UM-304 trial announced in December 2024. The CRL cited inspection findings, which the filing states were not specific to Zynyz, at Catalent Indiana, LLC, part of Novo Nordisk, the third-party fill-finish facility referenced in the sBLA. The filing states that regulatory compliance of Catalent Indiana was the sole approvability issue cited, and that the letter did not raise other approvability concerns, including the Zynyz efficacy and safety data in NSCLC or the third-party drug substance manufacturer.
Incyte says it is working closely with the FDA and Catalent Indiana to address the CRL and support a potential sBLA resubmission of Zynyz in NSCLC. The filing does not provide a timeline for resubmission.
02—Key points
Key Highlights
- FDA issued a Complete Response Letter on February 27, 2026 for the Zynyz (retifanlimab-dlwr) 375mg sBLA for metastatic NSCLC in combination with platinum-based chemotherapy.
- The sBLA was supported by positive efficacy and safety data from the Phase 3 POD1UM-304 trial, announced in December 2024.
- The CRL cited inspection findings at Catalent Indiana, LLC (part of Novo Nordisk), a third-party fill-finish facility, as the sole approvability issue.
- The inspection findings were described as not specific to Zynyz.
- The CRL did not cite the Zynyz efficacy and safety data in NSCLC or the third-party drug substance manufacturer as approvability concerns.
- Incyte is working with the FDA and Catalent Indiana to address the CRL and support a potential sBLA resubmission.
03—Questions
Frequently Asked Questions
What did the FDA decide on Zynyz for lung cancer?
On February 27, 2026, the FDA issued a Complete Response Letter for the sBLA seeking approval of Zynyz (retifanlimab-dlwr) 375mg for metastatic non-small cell lung cancer in combination with platinum-based chemotherapy. A CRL means the application was not approved in its current form.
What was the reason cited in the Complete Response Letter?
The CRL cited inspection findings at Catalent Indiana, LLC, part of Novo Nordisk, the third-party fill-finish facility referenced in the sBLA. The filing states these findings were not specific to Zynyz and were the sole approvability issue cited.
Did the FDA raise concerns about the trial data?
According to the filing, the CRL did not cite Zynyz's efficacy and safety data in NSCLC as an approvability concern. The sBLA was supported by data from the Phase 3 POD1UM-304 trial, announced in December 2024.
What happens next for Zynyz in NSCLC?
Incyte is working closely with the FDA and Catalent Indiana to address the CRL and support a potential sBLA resubmission of Zynyz in NSCLC. The filing does not state a resubmission timeline.
Does the issue affect the third-party drug substance manufacturer?
No. The filing states the CRL did not cite the third-party drug substance manufacturer as an approvability concern. The cited issue relates to the fill-finish facility, Catalent Indiana.
04—Continue